Ecnoglutide (5mg/10mg)

What is Ecnoglutide?

Ecnoglutide is a GLP-1 peptide analogue studied for cAMP-biased signaling. This catalog offers 5mg and 10mg research vials. Ecnoglutide is not mazdutide, whose development name is IBI362.

Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Biased signaling means a molecule favors one receptor response relative to another. cAMP is an intracellular signaling molecule; beta-arrestin is a protein involved in receptor regulation. The bias depends on the assay and comparator, not only the compound name.

What are the research questions?

• cAMP signaling and beta-arrestin responses
• Assay-dependent receptor bias
• Separating signaling hypotheses from clinical glucose outcomes

What does the published work describe?

Zhu and colleagues' 2026 EECOH-1 paper describes a randomized, placebo-controlled phase 3 trial in adults with type 2 diabetes. It examined ecnoglutide monotherapy in a defined clinical preparation. Trial outcomes do not prove that receptor bias explains every observed effect or verify this supplied material.

Experimental models in the cited papers

• EECOH-1: randomized, double-blind phase 3 human type 2 diabetes trial

What could future research explore?

Matched cell assays can test the reproducibility of signaling bias. Future work should examine whether specific receptor responses explain clinical endpoints rather than assuming that a mechanistic hypothesis is established.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.

Study references

1. Zhu D, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026. PMID 41501026

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.